Clinical report

Outbreak of lead poisoning associated with ayurvedic medicine

Sara Fernández a, Gerónimo-Antonio Pollio a, Verónica Domínguez a, Santiago Nogué b, a, Mercè Torra c, Francesc Cardellach a

a Servicio de Medicina Interna, Hospital Clinic, Barcelona, Spain
b Sección de Toxicología Clínica, Hospital Clinic, Barcelona, Spain
c Sección de Toxicología Analítica, Hospital Clinic, Barcelona, Spain

A R T I C L E   I N F O

Article history:
Received 6 September 2013
Accepted 12 September 2013
Available online 23 October 2015

Keywords:
Saturnism
Lead poisoning
Ayurvedic medicine

A B S T R A C T

Background and objective: Lead poisoning is normally caused by repeated occupational inhalation of lead. However, lead may also be absorbed through the digestive route. Some alternative medical treatments, such as ayurvedic medicine, can also contain lead and may result in poisoning.

Patients and methods: We collected cases of lead poisoning related to Ayurvedic treatments attended at the Hospital Clinic of Barcelona.

Results: Two female patients, aged 45 and 57 years, respectively, who initiated ayurvedic treatments which involved the ingestion of various medications, were included. The first patient presented with anaemia and abdominal pain. The lead level was 74 μg/dl and free erythrocyte protoporphyrin was 163 μg/dl. She was treated with intravenous calcium disodium ethylenediaminetetraacetic acid (CaNa₂EDTA) and later with oral dimercaptosuccinic acid (DMSA) with a good evolution. The second patient presented with abdominal pain and a Burton’s line. The lead level was 52 μg/dl and free erythrocyte protoporphyrin was 262 μg/dl. She was treated with oral DMSA and evolved favourably. Lead concentrations in some of the tablets supplied to the patients reached 2003 and 19,650 μg/g of tablet.

Conclusions: Lead poisoning may result from treatments based on ayurvedic medicine and may reach epidemic proportions. Health control of alternative medicines is necessary.

© 2013 Elsevier España, S.L.U. All rights reserved.

Brote de saturnismo asociado a un tratamiento basado en la medicina ayurvédica

R E S U M E N

Fundamento y objetivo: El saturnismo es una enfermedad de causa tóxica que se produce, habitualmente, por la inhalación repetida de plomo en un ámbito laboral. Pero este metal puede también ser absorvido por vía digestiva. En medicinas alternativas, como la ayurvédica, el plomo puede formar parte de algunos tratamientos y ser causa de intoxicación.

Pacientes y método: Se recogen los casos de saturnismo atendidos y tratados en el Hospital Clínic de Barcelona en relación con un tratamiento ayurvédico.

Resultados: Se han incluido 2 mujeres de 45 y 57 años que iniciaron un tratamiento ayurvédico que comprendía la ingesta de diversos medicamentos. El primer caso desarrolló anemia y dolor abdominal. La plumbemia fue de 74 μg/dl y la protoporfirina eritrocitaria de 163 μg/dl. Fue tratada con etilendiaminotetraacetato de calcio y disodio (CaNa₂EDTA) intravenoso y posteriormente con ácido dimercaptosuccínico (DMSA) oral, con buena evolución. El segundo caso presentó dolor abdominal y un ribete de Burton. La plumbemia fue de 52 μg/dl y la protoporfirina eritrocitaria de 262 μg/dl. Fue tratada con DMSA oral,
Introduction

Plumbism or lead poisoning is usually an occupational disease from the inhalation of this metal in several types of industry, mainly those in which this toxic metal is smelted. However, there are other potential sources of plumbism, either by dust inhalation or ingestion of contaminated foods or drinks that may cause epidemic outbreaks. 1

Ayurvedic medicine, together with traditional Chinese medicine, is one of the world’s oldest health care systems still in force. Of Indian origin, ayurvedic medicine includes herbal medications and diet while focusing on the use of the body, the mind and the spirit in the prevention and treatment of diseases. In Western countries, ayurveda is considered an alternative medical system; in Spain, as in other European and American countries, it is possible to find health care centres involved in this practice. However, although the pharmacological active substances on which this medicine is based come from plants, it is common (in up to 20% of this kind of medications) for these substances to be mixed with heavy metals such as lead, mercury, zinc, iron or arsenic because of their alleged therapeutic properties. 2 As a result, for the last 40 years, there have been case reports of iatrogenic poisoning with consequences mainly in the red blood cells, although toxic effects have also been described for other organs. 3–5

The objective of this study is to describe, for the first time in Spain, an outbreak of plumbism associated with treatment with ayurvedic medications containing high lead content.

Clinical observation

Case 1

The patient is a 45-year-old female carrier of thalassaemia minor who had no history of secondary anaemia and was under treatment with folic acid and vitamin B12. She was allergic to penicillin. The patient reported symptoms of asthenia and colic-type abdominal pain during the previous 2 months, and there were no noteworthy findings in the physical examination. In the laboratory blood tests, microcytic and hypochromic anaemia (haemoglobin 6.6 g/dl, haematocrit 20.6%) were verified with basophilic stippling (Fig. 1); no haemolysis, iron or vitamin deficiencies were observed. Several supplementary examinations were performed (chest X-ray, occult blood in stool, upper and lower digestive endoscopy, bone marrow aspiration, ultrasound scan and abdominal computed tomography), which did not show significant abnormalities. Although the patient did not report any source of lead exposure, a toxicological analysis was requested, which showed a blood concentration of this metal of 74 μg/dl (normal value <20 μg/dl). Elevated concentrations of erythrocyte protoporphyrin (163 μg/dl), mainly zinc protoporphyrin (85% of the erythrocyte protoporphyrin), as well as of delta-aminolevulinic acid in the urine were verified, thus establishing a diagnosis of plumbism.

The patient did not perform any work, household activities or hobbies related with lead exposure. There was no previous history of contact with petrol, paint, ceramics or other common sources of exposure. The water at her house was analysed, and potable lead levels were verified (<3 μg/l). Re-questioning revealed that, 2 months before, she had started an ayurvedic treatment for shoulder bursitis and was taking tablets a day of 3 medications, with no packaging or patient information leaflet, that were given to her at an “aesthetic and therapy centre” in a community located near Barcelona. An X-ray of one of the medications (Mahavatvihwansa Rasa [MVV]) showed elevated radiodensity (Fig. 1), and the toxicological analysis of the pill showed a lead concentration of 203 μg/g per pill. Some of the other medications also contained lead, but in smaller quantities ranging from 4 to 86 μg/g of pill, so the overall estimated daily consumption was 916 μg of lead, totalling 60 g of lead over the 2 months of treatment. The possible concomitant presence of mercury and arsenic was studied, but the results were negative.

Chelating treatment was initiated via intravenous line with calcium and disodium ethylenediaminetetraacetic acid (CaNa2EDTA, 2 g/day), 5 days a week, for 2 weeks. The evolution of lead levels in blood and urine is shown in Table 1. After discharge from the hospital, she received oral ambulatory treatment with dimercaptosuccinic acid (DMSA, 10 mg/kg/8 h, 5 days a week, 2 weeks) until a blood lead level of 13 μg/dl was achieved with normalisation of porphyrins and disappearance of clinical manifestations. Both treatments were well tolerated.

Case 2

The patient is a 57-year-old female with history of fibromyalgia who had been treated at the same ayurvedic centre as the previous case due to her baseline disease. She was prescribed a treatment that was given to her in unlabelled plastic bags with 4 types of pills. She had to take 3 tablets of each per day. Some 3 months later, she abandoned the treatment because of abdominal pain. Warned by

Fig. 1. (A) Blood smear from case 1. May–Grünewald–Giemsa stain. A basophilic stippling (arrows) is observed on some of the red blood cells (image courtesy of Josep Luís Aguilar, MD); (B) X-ray of some of the ayurvedic medications ingested by the patient. The group on the left, labelled as Mahavatvihwansa Rasa (MVV), is very radiodense and the lead concentration in one of them was 203 μg/g per pill.
Table 1
Case 1. Blood lead concentration and urine lead concentration and amount of lead excreted through urine of 24 h at the beginning, during and at the end of the treatment with chelating agents.

<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th>Treatment 1 (CaNa₂EDTA)</th>
<th>Baseline</th>
<th>Treatment 2 (CaNa₂EDTA)</th>
<th>Baseline</th>
<th>Treatment 3 (DMSA)</th>
<th>Baseline</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Day 1</td>
<td>Day 2</td>
<td>Day 3</td>
<td>Day 4</td>
<td>Day 5</td>
<td>Day 1</td>
<td>Day 2</td>
</tr>
<tr>
<td>Blood Pb (µg/dl)</td>
<td>66</td>
<td>–</td>
<td>–</td>
<td>30</td>
<td>23</td>
<td>28</td>
<td>–</td>
</tr>
<tr>
<td>Urine Pb (µg/l)</td>
<td>65</td>
<td>1079</td>
<td>650</td>
<td>755</td>
<td>530</td>
<td>360</td>
<td>51</td>
</tr>
<tr>
<td>Urine (ml/24h)</td>
<td>–</td>
<td>600</td>
<td>3200</td>
<td>2400</td>
<td>2600</td>
<td>3000</td>
<td>2500</td>
</tr>
<tr>
<td>Urine Pb 24h (µg)</td>
<td>–</td>
<td>647</td>
<td>2080</td>
<td>1812</td>
<td>1219</td>
<td>1080</td>
<td>128</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CaNa₂EDTA, calcium and disodium ethylenediaminetetraacetic; DMSA, dimercapto succinic acid; Pb, lead.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The health care authorities about a risk of plumbism as a result of the diagnosis from case 1, toxicological analyses were performed that showed a blood lead concentration of 52 µg/dl and a urine lead concentration of 43.2 µg/l. Although there was no anaemia (12.5 g/dl of haemoglobin), erythrocyte porphyrin was very high (262 µg/dl) at the expense of the zinc protoporphyrin (91%). The physical examination was normal, except for the presence of a Burton line (Fig. 2). One of the medications was also radio-opaque (Fig. 2) and its toxicological analysis showed that it contained 19,650 µg of lead per gram of pill. An ambulatory treatment was initiated with DMSA at a dose of 10 mg/kg/8 h, 5 days a week, during 2 weeks, with good tolerance. When the treatment ended, the patient was asymptomatic, blood lead level was 14 µg/dl and erythrocyte protoporphyrin was 59 µg/dl.

Discussion
Plumbism is a multifaceted poisoning that is hard to diagnose if the source of exposure is not occupational, although some clinical signs (abdominal pain of unknown cause, Burton line) and biological signs (anaemia with basophilic stippling) allow for suspicion.10-11

For several years now, cases of plumbism associated with ayurvedic medication have been published, but, so far, never in Spain. The medications always come from India or Southern Asia.12 The presence of heavy metals is not usually caused by accidental contamination. Some of these medications (rasa shastra) contain arsenic, mercury or lead in the belief that they have therapeutic capabilities.10

Lead is orally absorbable and, if daily intake surpasses 200 µg, there is a risk of accumulation and development of toxicity in very few weeks. The availability of these medications via Internet and their possible adulteration increase the risk for the population and the possibilities of an epidemic outbreak.14,15 Fortunately, there are several antidotes for lead poisoning with great chelating capacity. They increase urinary excretion and notably reduce elimination half-life, resolving clinical and biological disorders in a few weeks, although there is a risk of neurological sequelae.16 Children are particularly sensitive to the neurotoxicity of lead, so medications of the rasa shastra type should never be prescribed to children or pregnant women.12

These cases were reported to the public health area of the city council where the therapeutic centre is located and to the Public Health Department of the Generalitat de Catalunya, which proceeded to confiscate the stock of involved medications and to locate other people that had been administered this medication. Some of the patients that received the same type of ayurvedic treatment were checked at our hospital, and no other cases of poisoning were detected. A notification was also sent to the National Pharmacovigilance System. The Spanish Agency of Medicines and Medical Devices (Agencia Española de Medicamentos y Productos Sanitarios) informed that MVV is a product that is not authorised in Spain.17 It is necessary for the strict control applied on the drugs available in our setting be also applied to alternative medications.18

Even though Hippocrates (460-370 BC) had already described painters’ colic, 25 centuries later lead poisoning is still present in our setting and, sometimes, those who prescribe the medications are the ones who can make this disease break out again.

Conflict of interests
The authors declare that there are no conflicts of interest.

References


